Project Grant R15DK136103
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $851,275 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 15, 2026, with a completion date of December 31, 2029. The research project, titled "Mechanisms Regulating Competency of Hepatocyte Plasticity," investigates...
- This federal Project Grant award of $460,500 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) is aimed at developing novel bioprinting methodologies for the production of human stem cell-based organoids. The key objectives are to: 1) Create a customized bioink formulation using proteins, polysaccharides, and functionalized nanoparticles to foster the...
- Federal Project Grant Summary: Intraductal Gene Therapy for Liver Cirrhosis Oregon Health & Science University (OHSU) received a $686,129 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded January 16, 2026, with a completion date of November 30, 2029. The research systematically explores the intraductal route of administration for gene therapy...
- Federal Project Grant Award Summary Oregon Health & Science University received a $1,992,234 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025, through April 30, 2030. This award funds research on allogeneic hepatocyte transplantation designed to overcome critical barriers to therapeutic liver cell therapy by developing genetically...
- The University of Pennsylvania received a $665,725 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2026, with a completion date of December 31, 2029. This research initiative delivers fundamental biomedical research and molecular genetic analysis focused on understanding the role of cellular senescence in liver disease...
- The National Science Foundation awarded a $1,064,877 project grant to the University of Pittsburgh under the Engineering program (CFDA 47.041) to support research titled "COLLABORATIVE RESEARCH: RECODE: DIRECTED DIFFERENTIATION OF HUMAN LIVER ORGANOIDS VIA COMPUTATIONAL ANALYSIS AND ENGINEERING OF GENE REGULATORY NETWORKS." The three-year award beginning January 1, 2022 will fund development of computational models to analyze gene regulatory networks and direct differentiation of human...
- Federal Cooperative Agreement Summary UC San Diego Health received a $18.3 million Cooperative Agreement from the Advanced Research Projects Agency for Health (ARPA-H, CFDA 93.384) awarded on September 25, 2025, with a completion date of September 24, 2028. The award supports the development of a scalable, patient-specific bioprinted liver using induced pluripotent stem cells (iPSCs). The deliverable is a functional, on-demand liver tissue tailored to individual patient anatomy and physiology...
- Federal Grant Award Summary Funding Agency: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Federal Grant Program: Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) Award Amount: $469,042 Award Period: September 1, 2025 – August 31, 2027 Awardee: The Children's Hospital Corporation (Boston Children's Hospital) Boston Children's Hospital will develop and optimize a human induced pluripotent stem cell (iPSC)-derived bone marrow organoid as an...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston (UTHealth) received a $2,618,975 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 8, 2025, with a completion date of September 7, 2029. This five-year research initiative focuses on advancing intestinal tissue engineering to develop functional...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant, awarded to Tissueform, Inc., a for-profit woman-owned small business in Boulder, Colorado, aims to develop a library of human-based bioinks for 3D bioprinting applications. The $274,822 award, with a performance period from September 2024 to August 2025, will focus on creating granulated bioinks for tissues such as cartilage, bone, skin, liver,...
DEVELOPMENT OF COMPLEX LIVER ORGANOIDS USING CELL-SPECIFIC PATTERNED BIOMATERIALS - LIVER BILE-DUCT DISEASES ARE ONE OF THE MAIN CAUSES OF LIVER TRANSPLANTATION, AND OFTEN RESULT IN LIVER CIRRHOSIS, AFFECTING MILLIONS OF US CITIZENS. CURRENT HUMAN LIVER ORGANOIDS LACK INTEGRATED BILE DUCTS, WHICH MAKES IT DIFFICULT TO ACCURATELY MODEL LIVER DISEASES DUE TO A LACK OF BILE-TRANSPORT SYSTEM. LIVER ORGANOIDS CONTAINING BILE DUCTS HAVE BEEN DIFFICULT TO CREATE BECAUSE THE HEPATOCYTES AND BILE-DUCT CELLS IN THE LIVER HAVE VASTLY DIFFERENT NEEDS FOR BOTH NOTCH SIGNALING AND BIOMECHANICAL CUES, WHICH THE CURRENT 3D-CULTURE TECHNIQUES ARE NOT CAPABLE OF PROVIDING SIMULTANEOUSLY. THUS, THERE IS A CRITICAL NEED FOR A TECHNOLOGY THAT CAN SIMULTANEOUSLY DELIVER TARGETED NOTCH SIGNALING AND BIOMECHANICAL CUES TO BOTH TYPES OF LIVER CELLS IN CO-CULTURE, IN ORDER TO MAINTAIN THEIR MATURATION. EXCITING PRELIMINARY STUDIES INDICATE THAT THE DUAL-BIOINK-BASED BIOPRINTED CONSTRUCTS CAN PROVIDE CELL-TYPE-SPECIFIC SIGNALS WITHIN A CO-CULTURE MATRIX. MOREOVER, BUILDING ON THEIR PREVIOUS WORK, THE PI HAS DEVELOPED NEW ENGINEERED MATRIX TO PRECISELY TUNE THE BIO-MECHANICAL CUES (STIFFNESS AND VISCOELASTICITY) IN A CELL-SPECIFIC MANNER, WHICH SUPPORTS THE GROWTH OF 3D HUMAN BILE-DUCT NETWORK. ACCORDINGLY, THE OBJECTIVE OF THIS PROPOSAL IS TO EVALUATE AND OPTIMIZE THE EFFECT OF PATTERNED NOTCH SIGNALING AND BIO-MECHANICAL CUES IN CO-CULTURED LIVER CELLS TO DEVELOP LIVER ORGANOIDS WITH INTEGRATED BILE-FLOW SYSTEM. THE RATIONALE IS THAT LIVER ORGANOIDS WITH INTEGRATED BILE-FLOW SYSTEM WILL MIMIC LIVER FUNCTION, THUS WILL IMPROVE DISEASE MODELLING AND DRUG TESTING. THE PROPOSED RESEARCH WILL PURSUE TWO SPECIFIC AIMS: (1) DETERMINE THE EFFECT OF SPATIO-TEMPORAL NOTCH ACTIVATION ON LIVER ORGANOID FUNCTIONS, AND (2) OPTIMIZE THE MATURATION OF LIVER ORGANOID VIA CELL-TYPE-SPECIFIC BIOMECHANICAL CUES. IN THE FIRST AIM, BIOPRINTED CONSTRUCTS WILL BE DEVELOPED USING TWO DISTINCT, CELL-LADEN BIOINKS WITH AND WITHOUT PHOTO- ACTIVATABLE NOTCH LIGANDS, TO ACHIEVE TARGETED NOTCH ACTIVATION IN CO-CULTURE. THE ORGANOIDS WILL BE ANALYZED USING NOTCH TARGET GENES AND A RANGE OF LIVER FUNCTIONAL ASSAYS. IN THE SECOND AIM, AN 18-CONDITION MATRIX SCREEN WILL BE DEVELOPED TO SYSTEMATICALLY EVALUATE AND OPTIMIZE THE EFFECT OF PATTERNED BIOMECHANICAL CUES ON LIVER ORGANOIDS IN A BIOPRINTED CO-CULTURE CONSTRUCT. FINALLY, THE MECHANO-SENSING MECHANISM WILL BE EVALUATED IN CO-CULTURE CONSTRUCT. THE PROPOSED RESEARCH IS EXPECTED TO BE SIGNIFICANT BECAUSE IT WILL LEVERAGE TARGETED NOTCH SIGNALING AND BIOMECHANICAL CUES TO INFORM THE DEVELOPMENT OF LIVER ORGANOIDS WITH INTEGRATED BILE DUCTS FOR THERAPEUTIC APPLICATIONS, AND WILL TRAIN A DIVERSE GROUP OF UNDERGRADUATE STUDENTS IN THE AREA OF BIOPRINTING, BIOMATERIALS, AND LIVER TISSUE ENGINEERING.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($29k) | 7/22/25 | ||
| Not listed | $0 | 6/11/25 | ||
| Not listed | $0 | 6/11/25 | ||
| Not listed | $443.4k | 8/31/23 |